Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Role of altered CD40-Ligand gene transcription in systemic lupus erythematosus Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Role of altered CD40-Ligand gene transcription in systemic lupus erythematosus conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Role of altered CD40-Ligand gene transcription in systemic lupus erythematosus Clinical research trials and Role of altered CD40-Ligand gene transcription in systemic lupus erythematosus healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Role of altered CD40-Ligand gene transcription in systemic lupus erythematosus. Role of altered CD40-Ligand gene transcription in systemic lupus erythematosus Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Role of altered CD40-Ligand gene transcription in systemic lupus erythematosus clinical trial. Human subjects often receive the most effective healthcare possible for their Role of altered CD40-Ligand gene transcription in systemic lupus erythematosus condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.

Home > "R" Clinical Trials Conditions > Role of altered CD40-Ligand gene transcription in systemic lupus erythematosus

Role of altered CD40-Ligand gene transcription in systemic lupus erythematosus



Role of altered CD40-Ligand gene transcription in systemic lupus erythematosus

For Condition: Lupus Erythematosus, Systemic
Status: Recruiting
Sponsor(s): National Center for Research Resources (NCRR) , Arthritis Foundation
Synopsis: Systemic lupus erythematosus is an often devastating autoimmune disease which affects 1 in 2,000 women in the United States. Recently, several research laboratories have reported that a protein, named CD40-ligand (CD154), is overexpressed by a subset of white blood cells, called lymphocytes, in patients with lupus. Expression of CD154 appears critical to the generation of antibodies that cause disease in lupus. Blocking CD154 interactions in the immune system has been shown to decrease disease activity in animal models of lupus. We propose to study the regulation of CD154 in patients with lupus in hopes of inhibiting its abnormal and deleterious expression.
Details:
Eligibility:
Study Type:
  Observational, Natural History, Case Control
Minimum Age/Maximum Age: 13 Years/
Genders: Both
Protocol Entry Criteria: Inclusion: A diagnosis of systemic lupus erythematosus
Total Enrollment: 

Location and Contact Information:

Children's Hospital of Philadelphia *Recruiting*
Philadelphia,  Pennsylvania,  19104-4318
United States
Recruiting Randy  Cron 215-590-1844


Additional Information:
Study ID Numbers:
  NCRR-M01RR00240-1736; 
Study Start Date: 
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00008749

Other Lupus Erythematosus, Systemic Studies:
1. Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus

2. Anti-CD20 in Systemic Lupus Erythematosus

3. Study of LymphoStat-B in Subjects with Systemic Lupus Erythematosus (SLE)

4. Six month clinical research study for patients with moderate or severe dry eye syndrome

5. Role of altered CD40-Ligand gene transcription in systemic lupus erythematosus

Related Studies:

Other Lupus Erythematosus, Systemic Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials

Role of altered CD40-Ligand gene transcription in systemic lupus erythematosus

Modify your Search

  Other Lupus Erythematosus, Systemic Clinical Trials
  Other Pennsylvania Clinical Trials
  Other Philadelphia Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103